Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab

• Published in: Oncogene Vol. 38; no. 18; pp. 3458 - 3474
• Main Authors: Wang, Dawei, Xu, Qingqing, Yuan, Quan, Jia, Mengqi, Niu, Huanmin, Liu, Xiaofei, Zhang, Jinsan, Young, Charles Yf, Yuan, Huiqing
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01-05-2019; Nature Publishing Group
• Subjects: 38/61; 38/77; 38/89; 42/109; 42/35; 45/70; 631/67/1059/2326; 631/80/474/582; 82/51; 82/79; A549 Cells; Angiogenesis; Animals; Antineoplastic Agents; Antitumor activity; Apoptosis; Autophagy; Autophagy - drug effects; Bevacizumab; Bevacizumab - pharmacology; Bortezomib; Bortezomib - pharmacology; Cancer; Cancer cells; Cell Biology; Cell Line; Cell Line, Tumor; Chemotherapy; Dosage and administration; Gene expression; Gene silencing; Genetic aspects; Human Genetics; Humans; Immunotherapy; Internal Medicine; Kinases; Ligases; Lung cancer; Male; Medical research; Medicine; Medicine & Public Health; Messenger RNA; Mice; Mice, Inbred BALB C; Mice, Nude; Monoclonal antibodies; Oncology; Pancreatic cancer; Phagocytosis; Polyubiquitin - metabolism; Proteasome Endopeptidase Complex - metabolism; Proteasome inhibitors; Proteasome Inhibitors - pharmacology; Protein disulfide-isomerase; Proteins; Proteins - metabolism; Rapamycin; RNA; Targeted cancer therapy; Transcription (Genetics); Tumors; Ubiquitin - metabolism; Ubiquitin-protein ligase; Ubiquitin-Protein Ligases - metabolism; Ubiquitination - drug effects
• ISSN: 0950-9232; 1476-5594
• DOI: 10.1038/s41388-019-0675-z

Anterior gradient 2 (AGR2), a protein belonging to the protein disulfide isomerase (PDI) family, is overexpressed in multiple cancers and promotes angiogenesis to drive cancer progression. The mechanisms controlling AGR2 abundance in cancer remain largely unknown. Here, we observed that AGR2 expression is significantly suppressed by proteasome inhibitor MG132/bortezomib at mRNA and protein levels in lung cancer cells. MG132-mediated repression of AGR2 transcription was independent of ROS generation and ER stress induction, but partially resulted from the downregulated E2F1. Further investigation revealed that MG132 facilitated polyubiquitinated AGR2 degradation through activation of autophagy, as evidenced by predominant restoration of AGR2 level in cells genetic depletion of Atg5 and Atg7, or by autophagy inhibitors. Activation of autophagy by rapamycin noticeably reduced the AGR2 protein in cells and in the mouse tissue samples administrated with bortezomib. We also provided evidence identifying the K48-linked polyubiquitin chains conjugating onto K89 of AGR2 by an E3 ligase UBR5. In addition, an autophagy receptor NBR1 was demonstrated to be important in polyubiquitinated AGR2 clearance in response to MG132 or bortezomib. Importantly, downregulation of AGR2 by proteasome inhibition significantly enhanced antitumor activity of bevacizumab, highlighting the importance of AGR2 as a predictive marker for selection of subgroup patients in chemotherapy.